Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cell Death Dis ; 5: e1449, 2014 Oct 09.
Artigo em Inglês | MEDLINE | ID: mdl-25299774

RESUMO

Recently, we reported that human neuroglobin (NGB) is a new player in the signal transduction pathways that lead to 17ß-estradiol (E2)-induced neuron survival. Indeed, E2 induces in neuron mitochondria the enhancement of NGB level, which in turn impairs the activation of a pro-apoptotic cascade. Nowadays, the existence of a similar pathway activated by E2 in non-neuronal cells is completely unknown. Here, the role of E2-induced NGB upregulation in tumor cells is reported. E2 induced the upregulation of NGB in a dose- and time-dependent manner in MCF-7, HepG2, SK-N-BE, and HeLa cells transfected with estrogen receptor α (ERα), whereas E2 was unable to modulate the NGB expression in the ERα-devoid HeLa cells. Both transcriptional and extranuclear ERα signals were required for the E2-dependent upregulation of NGB in MCF-7 and HepG2 cell lines. E2 stimulation modified NGB intracellular localization, inducing a significant reduction of NGB in the nucleus with a parallel increase of NGB in the mitochondria in both HepG2 and MCF-7 cells. Remarkably, E2 pretreatment did not counteract the H2O2-induced caspase-3 and poly (ADP-ribose) polymerase 1 (PARP-1) cleavage, as well as Bcl-2 overexpression in MCF-7 and HepG2 cells in which NGB was stably silenced by using shRNA lentiviral particles, highlighting the pivotal role of NGB in E2-induced antiapoptotic pathways in cancer cells. Present results indicate that the E2-induced NGB upregulation in cancer cells could represent a defense mechanism of E2-related cancers rendering them insensitive to oxidative stress. As a whole, these data open new avenues to develop therapeutic strategies against E2-related cancers.


Assuntos
Receptor alfa de Estrogênio/metabolismo , Globinas/metabolismo , Neoplasias/metabolismo , Neoplasias/fisiopatologia , Proteínas do Tecido Nervoso/metabolismo , Apoptose , Linhagem Celular Tumoral , Sobrevivência Celular , Estradiol/metabolismo , Receptor alfa de Estrogênio/genética , Globinas/genética , Humanos , Neoplasias/genética , Proteínas do Tecido Nervoso/genética , Neuroglobina
2.
Cell Death Dis ; 4: e508, 2013 Feb 21.
Artigo em Inglês | MEDLINE | ID: mdl-23429294

RESUMO

The sex steroid hormone 17ß-estradiol (E2) upregulates the levels of neuroglobin (NGB), a new neuroprotectant globin, to elicit its neuroprotective effect against H(2)O(2)-induced apoptosis. Several mechanisms could be proposed to justify the NGB involvement in E2 prevention of stress-induced apoptotic cell death. Here, we evaluate the ability of E2 to modulate the intracellular NGB localization and the NGB interaction with mitochondrial cytochrome c following the H(2)O(2)-induced toxicity. Present results demonstrate that NGB is expressed in the nuclei, mitochondria, and cytosol of human neuroblastoma SK-N-BE cells. E2, but not H(2)O(2) treatment of SK-N-BE cells, reallocates NGB mainly at the mitochondria and contemporarily reduces the number of apoptotic nuclei and the levels of cleaved caspase-3. Remarkably, the E2 treatment strongly increases NGB-cytochrome c association into mitochondria and reduces the levels of cytochrome c into the cytosol of SK-N-BE cells. Although both estrogen receptors (ERα and ERß) are expressed in the nucleus, mitochondria, and cytosol of SK-N-BE cells, this E2 effect specifically requires the mitochondrial ERß activity. As a whole, these data demonstrate that the interception of the intrinsic apoptotic pathway into mitochondria (i.e., the prevention of cytochrome c release) is one of the pivotal mechanisms underlying E2-dependent NGB neuroprotection against H(2)O(2) toxicity.


Assuntos
Apoptose/efeitos dos fármacos , Citocromos c/metabolismo , Estradiol/farmacologia , Globinas/metabolismo , Peróxido de Hidrogênio/toxicidade , Mitocôndrias/metabolismo , Proteínas do Tecido Nervoso/metabolismo , Regulação para Cima/efeitos dos fármacos , Caspase 3/metabolismo , Linhagem Celular Tumoral , Receptor alfa de Estrogênio/metabolismo , Receptor beta de Estrogênio/metabolismo , Globinas/antagonistas & inibidores , Globinas/genética , Células HeLa , Humanos , Mitocôndrias/efeitos dos fármacos , Proteínas do Tecido Nervoso/antagonistas & inibidores , Proteínas do Tecido Nervoso/genética , Neuroblastoma/metabolismo , Neuroblastoma/patologia , Neuroglobina , Interferência de RNA , RNA Interferente Pequeno/metabolismo , Transfecção
3.
Endocr Relat Cancer ; 13(2): 559-69, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16728582

RESUMO

Nitric oxide (NO) and 17beta-estradiol (E2) are both important in gastrointestinal health and disease. NO contributes to gastrointestinal motility as well as to inflammation and carcinogenic processes. By contrast, E2 reduces the incidence of colon adenoma and carcinoma by about 30%. We report the genomic and non-genomic E2-estrogen receptor (ER) beta-induced effects in human colon adenocarcinoma. The effect of NO on ERbeta activities was also assessed. The E2-ERbeta-dependent gene transcription was inhibited by exogenous NO, whereas some non-genomic E2-dependent effects (e.g. p38/MAP kinase), important for the activation of the apoptotic cascade, were unaffected by NO. However, NO impaired the E2-induced pro-apoptotic cascade in human colon adenocarcinoma cells by inhibiting caspase-3. The effects of NO may reflect chemical modification(s) of Cys residues present in the DNA recognition domain of ERbeta as well as in the caspase-3 active site. On the whole, high NO concentrations suppressed the E2 protective effects in the gastrointestinal tract, suggesting that the caspase-dependent apoptotic cascade may become critical under conditions of high redox stress such as occur under specific activation of the immune system by chronic infections or pathogen challenge.


Assuntos
Adenocarcinoma/metabolismo , Apoptose/efeitos dos fármacos , Inibidores de Caspase , Neoplasias do Colo/metabolismo , Receptor beta de Estrogênio/antagonistas & inibidores , Óxido Nítrico/toxicidade , Adenocarcinoma/genética , Caspase 3 , Caspases/metabolismo , Neoplasias do Colo/genética , Cisteína/efeitos dos fármacos , Cisteína/metabolismo , Ativação Enzimática/efeitos dos fármacos , Estradiol/farmacologia , Receptor beta de Estrogênio/agonistas , Receptor beta de Estrogênio/metabolismo , Humanos , Transcrição Gênica/efeitos dos fármacos , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...